1. Home
  2. ECVT vs ANAB Comparison

ECVT vs ANAB Comparison

Compare ECVT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ecovyst Inc.

ECVT

Ecovyst Inc.

HOLD

Current Price

$11.35

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$55.31

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECVT
ANAB
Founded
1935
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
ECVT
ANAB
Price
$11.35
$55.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$12.60
$62.20
AVG Volume (30 Days)
1.4M
408.9K
Earning Date
05-29-2026
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.79
EPS
N/A
N/A
Revenue
$723,515,000.00
$91,280,000.00
Revenue This Year
$6.38
$135.51
Revenue Next Year
$6.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.70
432.03
52 Week Low
$5.24
$14.01
52 Week High
$12.33
$57.74

Technical Indicators

Market Signals
Indicator
ECVT
ANAB
Relative Strength Index (RSI) 54.74 59.87
Support Level $8.04 $43.67
Resistance Level $11.85 $57.65
Average True Range (ATR) 0.40 3.44
MACD -0.07 -0.01
Stochastic Oscillator 30.00 77.64

Price Performance

Historical Comparison
ECVT
ANAB

About ECVT Ecovyst Inc.

Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: